Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia

Published:2016-06 Issue:6 Volume:16 Page:341-349.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Khoury Hanna J.,Goldberg Stuart L.,Mauro Michael J.,Stone Richard M.,Deininger Michael W.,Bradley-Garelik M. Brigid,Mohamed Hesham,Guilhot François

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Gleevec (imatinib) [prescribing information],2015

2. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

3. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

4. Sprycel (dasatinib) [prescribing information],2015

5. Tasigna (nilotinib) [prescribing information],2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib;Annals of Hematology;2024-09-13

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25

4. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study;Leukemia Research;2024-04

5. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3